This study adds to the understanding of the early complications associated with cardiovascular implantable electronic devices (CIEDs) and the institutional variability in the quality of CIED implantation.
A systematic review compared the safety and efficacy of prasugrel and ticagrelor in patients with ACS undergoing PCI.
Having atrial fibrillation, using home oxygen, having severe lung disease, or having a permanent pacemaker were predictive of lower health status after transcatheter mitral valve repair.
While wearable technology can provide substantial patient benefit, these devices carry significant privacy and security risks.
The safety risk of dermatoscope magnets in patients with cardiovascular implanted electronic devices was examined.
There is no difference between heparin and bivalirudin in terms of platelet aggregation or coagulation markers after pretreatment with ticagrelor in patients undergoing PPCI.
Same day hospital discharge has the potential increase the overall value of PCI care and save US hospitals approximately $577 million if implemented more consistently.
The Eluvia stent is designed to release paclitaxel for a 1-year time frame to prevent tissue regrowth that might otherwise block the stented artery.
The Agency reviewed real-world data from 80 patients who received the PK Papyrus Stents, finding that the stents were delivered successfully to the perforation site in 95% of patients with successful seals seen in 73 patients 91.3% of patients.
Increase in number of patients overall and aged 65 years and younger receiving TAVR.